The Society for Cardiovascular Angiography and Interventions (SCAI) and Canadian Association of Interventional Cardiology (CAIC) have formed the North American COVID-19 ST-Segment Elevation Myocardial Infarction Registry (NACMI). The study will be chaired by Tim Henry (SCAI) and Payam Dehghani (CAIC).
According to a press release, any COVID-19 positive patients or persons under investigation (PUI) with ST-segment elevation or new-onset left bundle branch block with a clinical correlate of myocardial ischaemia (chest pain, dyspnoea, cardiac arrest, haemodynamic instability) will be in enrolled.
The data will be compared to an age and gender-matched control population from the existing Midwest STEMI Consortium, which is a large (>15,000), prospective multicentre registry of consecutive STEMI patients. The NACMI registry has pending central IRB approval and will have an ECG and angiographic core lab.
Interested sites can designate a local principal investigator and contact either SCAI principal investigator Tim Henry ([email protected]), CAIC principal investigator Payam Dehghani ([email protected]) or the data coordinating centre ([email protected] or ross[email protected]) to obtain participating site information.
The press release reports that SCAI and CAIC believe that this registry “has the potential to provide critically important time-sensitive data to inform the management and treatment guidelines applicable to COVID-19 patients”.